PMID- 34330652 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 2 DP - 2022 Feb TI - High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. PG - 63.e9-63.e18 LID - S1078-1439(21)00297-0 [pii] LID - 10.1016/j.urolonc.2021.06.021 [doi] AB - INTRODUCTION: Molecular markers associated with breast cancer are assumed to be associated with outcome in non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We retrospectively investigated the association of the mRNA expression of estrogen receptor 1 (ESR1) and 2 (ESR2), progesterone receptor (PGR), MKI67, and HER2 (ERBB2) with recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) in 80 patients with stage T1 NMIBC. RESULTS: High expression of ESR2 (P = 0.003), ERBB2 (P < 0.001), and MKI67 (P = 0.029) was associated with shorter RFS. Only high ERBB2 was an independent prognostic factor for reduced RFS (HR = 2.98; P = 0.009). When sub stratifying the cohort, high ESR2 was associated with reduced RFS (P < 0.001), CSS (P = 0.037) and OS (P = 0.006) in patients without instillation therapy. High ESR2 was associated with reduced CSS (P = 0.018) and OS (P = 0.029) in females and with shorter RFS in both sexes (males: P = 0.035; females: P = 0.010). Patients with high ERBB2 showed reduced CSS (P = 0.011) and OS (P = 0.042) in females and reduced CSS (P = 0.012) in those without instillation, while RFS was significantly reduced irrespective of sex or instillation. CONCLUSION: High mRNA expression of ERBB2 is an independent predictor of reduced RFS in patients with stage T1 NMIBC. High ERBB2 and ESR2 are associated with reduced outcomes, especially in females and patients without instillation therapy. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. Electronic address: danijel.sikic@uk-erlangen.de. FAU - Eckstein, Markus AU - Eckstein M AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Weyerer, Veronika AU - Weyerer V AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Kubon, Jennifer AU - Kubon J AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany. FAU - Kunath, Frank AU - Kunath F AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Keck, Bastian AU - Keck B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Taubert, Helge AU - Taubert H AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Wach, Sven AU - Wach S AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210728 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Receptor, ErbB-2/*metabolism MH - Retrospective Studies MH - Risk Factors MH - Survival Analysis MH - Urinary Bladder Neoplasms/*genetics/mortality OTO - NOTNLM OT - ERBB2 OT - Estrogen receptor OT - HER2 OT - Non-muscle-invasive bladder cancer OT - Urothelial carcinoma COIS- Conflict of interest All authors declare no conflicts of interest. EDAT- 2021/08/01 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/07/31 06:27 PHST- 2021/04/26 00:00 [received] PHST- 2021/06/13 00:00 [revised] PHST- 2021/06/25 00:00 [accepted] PHST- 2021/08/01 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/07/31 06:27 [entrez] AID - S1078-1439(21)00297-0 [pii] AID - 10.1016/j.urolonc.2021.06.021 [doi] PST - ppublish SO - Urol Oncol. 2022 Feb;40(2):63.e9-63.e18. doi: 10.1016/j.urolonc.2021.06.021. Epub 2021 Jul 28.